Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).
Page 8 of 31